Show source-provided references
1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
10.3322/caac.21492 ↗2. (2019, October 04). The World Ovarian Cancer Coalition Atlas: Global Trends in Incidence, Mortality and Survival. Available online: https://www.semanticscholar.org/paper/THE-WORLD-OVARIAN-CANCER-COALITION-ATLAS-GLOBAL-IN/67b106416bcb66f605debf039b56ff37a530a288#citing-papers.
4. First-line treatment of advanced ovarian cancer: Current research and perspectives
10.1586/era.09.167 ↗5. Jaaback, K., Johnson, N., and Lawrie, T.A. (2011). Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst. Rev.
10.1002/14651858.CD005340.pub3 ↗7. Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. i
10.1016/j.ygyno.2005.06.055 ↗8. Raavé, R., de Vries, R.B.M., Massuger, L.F., van Kuppevelt, T.H., and Daamen, W.F. (2015). Drug delivery systems for ovarian cancer treatment: A systematic review and meta-analysis of animal studies. PeerJ, 3.
10.7717/peerj.1489 ↗11. Tabata, Y., and Ikada, Y. (2005). Phagocytosis of polymer microspheres by macrophages. New Polymer Materials, Springer.
14. Biodegradable cisplatin microspheres prepared by the solvent evaporation method: Morphology and release characteristics
10.1016/0168-3659(88)90054-5 ↗15. Polymer-coated albumin microspheres as carriers for intravascular tumour targeting of cisplatin
10.1007/BF00687320 ↗17. Reduction of systemic exposure and toxicity of cisplatin by encapsulation in poly-lactide-co-glycolide
20. Experimental and clinical evaluation of cisplatin-containing microspheres as intraperitoneal chemotherapy for ovarian cancer
22. Carboplatin -loaded PLGA microspheres for intracerebral injection: Formulation and characterization
10.1080/026520499288753 ↗26. A novel drug delivery system of intraperitoneal chemotherapy for peritoneal carcinomatosis using gelatin microspheres incorporating cisplatin
10.1016/j.surg.2013.04.054 ↗27. Fan, L., and Singh, S.K. (1989). Diffusion-Controlled Release. Controlled Release A Quantitative Treatment, Springer.
10.1007/978-3-642-74507-2 ↗28. Chudecka-Głaz, A., Szczeblińska, J., Cymbaluk-Płoska, A., Kohn, J., and El Fray, M. (2016). New poly (ester-amide) copolymers modified with polyether (PEAE) for anticancer drug encapsulation. J. Microencapsul., 33.
10.1080/02652048.2016.1228708 ↗30. Influence of TiO 2 Nanoparticles Incorporated into Elastomeric Polyesters on their Biocompatibility In Vitro and In Vivo
31. Nanocomposite Elastomeric Biomaterials for Myocardial Tissue Engineering Using Embryonic Stem Cell-derived Cardiomyocytes
10.1002/adem.201080078 ↗32. Biodegradable polymeric microspheres and nanospheres for drug delivery in the peritoneum
10.1002/jbm.a.30654 ↗35. ISO (2009). Biological Evaluation of Medical Devices—Part 5: Tests for in Vitro Cytotoxicity, ISO.
36. (2019, October 04). DrugBank Carboplatin. Available online: http://www.drugbank.ca/drugs/DB00958.
37. Pénzváltó, Z., Lánczky, A., Lénárt, J., Meggyesházi, N., Krenács, T., Szoboszlai, N., Denkert, C., Pete, I., and Győrffy, B. (2014). MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer. BMC Cancer, 14.
10.1186/1471-2407-14-837 ↗38. Helland, Ø., Popa, M., Bischof, K., Gjertsen, B.T., McCormack, E., and Bjørge, L. (2016). The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer. PLoS ONE, 11.
10.1371/journal.pone.0158208 ↗40. Influence of thermally exfoliated graphite on physicochemical, thermal and mechanical properties of copolyester nanocomposites
10.14314/polimery.2016.482 ↗42. The effects of nano-sized carbon fillers on the physico-chemical, mechanical, and biological properties of polyester nanocomposites
10.1016/j.eurpolymj.2018.08.012 ↗45. Sittampalam, G., and Coussens, N. (2004). Cell Viability Assays. Assay Guidance Manual, Eli Lilly & Company and the National Center for Advancing Translational Sciences.
48. Gynecologic Oncology Tumor platinum concentration following intraperitoneal administration of cisplatin versus carboplatin in an ovarian cancer model
10.1016/j.ygyno.2009.08.028 ↗49. Prevention of Carboplatin-induced Resistance in Human Ovarian Tumor Xenografts by Selenite